Article

Additive effects of clofibric acid and pyruvate dehydrogenase kinase isoenzyme 4 (PDK4) deficiency on hepatic steatosis in mice fed a high saturated fat diet.

Richard Roudebush Veterans Affairs Medical Center, Indianapolis, IN 46202, USA.
FEBS Journal (Impact Factor: 3.99). 03/2012; 279(10):1883-93. DOI: 10.1111/j.1742-4658.2012.08569.x
Source: PubMed

ABSTRACT Although improving glucose metabolism by inhibition of pyruvate dehydrogenase kinase 4 (PDK4) may prove beneficial in the treatment of type 2 diabetes or diet-induced obesity, it may have detrimental effects by inhibiting fatty acid oxidation. Peroxisome proliferator-activated receptor α (PPARα) agonists are often used to treat dyslipidemia in patients, especially in type 2 diabetes. Combinational treatment using a PDK4 inhibitor and PPARα agonists may prove beneficial. However, PPARα agonists may be less effective in the presence of a PDK4 inhibitor because PPARα agonists induce PDK4 expression. In the present study, the effects of clofibric acid, a PPARα agonist, on blood and liver lipids were determined in wild-type and PDK4 knockout mice fed a high-fat diet. As expected, treatment of wild-type mice with clofibric acid resulted in less body weight gain, smaller epididymal fat pads, greater insulin sensitivity, and lower levels of serum and liver triacylglycerol. Surprisingly, rather than decreasing the effectiveness of clofibric acid, PDK4 deficiency enhanced the beneficial effects of clofibric acid on hepatic steatosis, reduced blood glucose levels, and did not prevent the positive effects of clofibric acid on serum triacylglycerols and free fatty acids. The metabolic effects of clofibric acid are therefore independent of the induction of PDK4 expression. The additive beneficial effects on hepatic steatosis may be due to induction of increased capacity for fatty acid oxidation and partial uncoupling of oxidative phosphorylation by clofibric acid, and a reduction in the capacity for fatty acid synthesis as a result of PDK4 deficiency.

0 Followers
 · 
384 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Peroxisome Proliferator Activated Receptor alpha (PPARα) is a transcription factor that plays a major role in metabolic regulation. This review addresses the functional role of PPARα in intermediary metabolism and provides a detailed overview of metabolic genes targeted by PPARα, with a focus on liver. A distinction is made between the impact of PPARα on metabolism upon physiological, pharmacological, and nutritional activation. Low and high throughput gene expression analyses have allowed the creation of a comprehensive map illustrating the role of PPARα as master regulator of lipid metabolism via regulation of numerous genes. The map puts PPARα at the center of a regulatory hub impacting fatty acid uptake, fatty acid activation, intracellular fatty acid binding, mitochondrial and peroxisomal fatty acid oxidation, ketogenesis, triglyceride turnover, lipid droplet biology, gluconeogenesis, and bile synthesis/secretion. In addition, PPARα governs the expression of several secreted proteins that exert local and endocrine functions.
    07/2014; 3(4). DOI:10.1016/j.molmet.2014.02.002
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Metabolic flexibility is the capacity of a system to adjust fuel (primarily glucose and fatty acids) oxidation based on nutrient availability. The ability to alter substrate oxidation in response to nutritional state depends on the genetically influenced balance between oxidation and storage capacities. Competition between fatty acids and glucose for oxidation occurs at the level of the pyruvate dehydrogenase complex (PDC). The PDC is normally active in most tissues in the fed state, and suppressing PDC activity by pyruvate dehydrogenase (PDH) kinase (PDK) is crucial to maintain energy homeostasis under some extreme nutritional conditions in mammals. Conversely, inappropriate suppression of PDC activity might promote the development of metabolic diseases. This review summarizes PDKs' pivotal role in control of metabolic flexibility under various nutrient conditions and in different tissues, with emphasis on the best characterized PDK4. Understanding the regulation of PDC and PDKs and their roles in energy homeostasis could be beneficial to alleviate metabolic inflexibility and to provide possible therapies for metabolic diseases, including type 2 diabetes (T2D).
    Nutrition & Metabolism 02/2014; 11(1):10. DOI:10.1186/1743-7075-11-10 · 3.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) is a major public health concern in the obese and type 2 diabetic populations. The high fat lard diet (HFD) induces obesity and fatty liver in C57BL/6J mice and suppresses expression of the PPAR-target gene, fatty acid elongase-5 (Elovl5). Elovl5 plays a key role in MUFA and PUFA synthesis. Increasing hepatic Elovl5 activity in obese mice lowered hepatic triglyceride (TG) and endoplasmic reticulum stress markers (XBP-1, ATF6 alpha) and increased TG catabolism and fatty acyl carnitines. Increased hepatic Elovl5 activity did not increase hepatic capacity for beta oxidation. Elovl5 effects on hepatic TG catabolism were linked to increased protein levels of adipocyte triglyceride lipase (ATGL) and comparative gene identification-58 (CGI58). Elevated hepatic Elovl5 activity also induced the expression of some [pyruvate dehydrogenase kinase-4 [PDK4], fibroblast growth factor-21], but not other (CYP4A10) PPAR-target genes. Fatty acid products of Elovl5 activity increased ATGL, but not CGI58, mRNA through PPAR beta dependent mechanisms in human HepG2 cells. Treatment of mouse AML12 hepatocytes with the PPAR beta agonist (GW0742) decreased 14C-18:2,n-6 in triglycerides, but did not affect beta oxidation. These studies establish that Elovl5 activity regulates hepatic levels of fatty acids controlling PPAR beta activity, ATGL expression and TG catabolism, but not fatty acid oxidation.
    The Journal of Lipid Research 05/2014; 55(7). DOI:10.1194/jlr.M050062 · 4.73 Impact Factor

Preview

Download
0 Downloads
Available from